Reaction
Injection Site Dryness reporting signals
As of the last recalculation, Injection Site Dryness appears in 873 FAERS reports alongside 12 co-occurring drug terms. The strongest observed disproportionality signal is PEGINTERFERON BETA-1A (PRR 39.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Peginterferon Beta-1A | 21 | 39.1 | 39.2 |
| Dupilumab | 389 | 33.9 | 33.9 |
| Sarilumab | 31 | 29.0 | 29.0 |
| Belimumab | 21 | 16.2 | 16.2 |
| Asfotase Alfa | 6 | 14.4 | 14.4 |
| Alirocumab | 14 | 13.5 | 13.5 |
| Interferon Beta-1B | 10 | 12.6 | 12.6 |
| Inclisiran | 3 | 8.9 | 8.9 |
| Budesonide, Glycopyrrolate, And Formoterol Fumarate | 3 | 6.9 | 6.9 |
| Rimegepant Sulfate | 3 | 5.7 | 5.7 |
| Galcanezumab-Gnlm | 5 | 3.8 | 3.8 |
| Tirzepatide | 19 | 2.8 | 2.8 |